Skip to content

Citius Pharmaceuticals, Inc.: 10-Q filed 2021-08-12

What Citius Pharmaceuticals, Inc. reported in its quarterly report filed 2021-08-12 (fiscal Q3 2021): 35 published measures, 99 facts as tagged in accession 0001213900-21-042071.

This filing

Form
10-Q (quarterly report)
Filed
2021-08-12
Fiscal period
fiscal Q3 2021
Accession
0001213900-21-042071 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-06-30146,592,848USD
At 2020-09-3043,773,655USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-06-309,310,895USD
At 2020-09-3010,102,987USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-06-30136,681,573USD
At 2020-09-3033,670,668USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-06-30115,663,976USD
At 2020-09-3013,859,748USD
At 2020-06-308,517,339USD
At 2019-09-307,893,804USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-04-01 to 2021-06-30-5,824,008USD91
2020-10-01 to 2021-06-30-18,093,349USD273
2020-04-01 to 2020-06-30-4,680,118USD91
2019-10-01 to 2020-06-30-13,427,457USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-10-01 to 2021-06-30-18,659,384USD273
2019-10-01 to 2020-06-30-13,572,866USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-10-01 to 2021-06-306,938USD273
2019-10-01 to 2020-06-301,831USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-10-01 to 2021-06-30120,470,550USD273
2019-10-01 to 2020-06-3014,198,232USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-10-01 to 2021-06-30-6,938USD273
2019-10-01 to 2020-06-30-1,831USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-06-30-91,086,736USD
At 2020-09-30-70,593,867USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-04-01 to 2021-06-30423USD91
2020-10-01 to 2021-06-301,234USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-06-307,754USD
At 2020-09-301,577USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-04-01 to 2021-06-30373,570USD91
2020-10-01 to 2021-06-30993,114USD273
2020-04-01 to 2020-06-30175,011USD91
2019-10-01 to 2020-06-30554,228USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-04-01 to 2021-06-30-5,984,406USD91
2020-10-01 to 2021-06-30-18,328,651USD273
2020-04-01 to 2020-06-30-4,688,891USD91
2019-10-01 to 2020-06-30-13,569,911USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-06-30116,935,371USD
At 2020-09-3013,981,985USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2021-04-01 to 2021-06-302,932USD91
2020-10-01 to 2021-06-3010,839USD273
2020-04-01 to 2020-06-304,245USD91
2019-10-01 to 2020-06-3012,216USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-06-303,600,310USD
At 2020-09-304,097,133USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2021-06-301,354,664USD
At 2020-09-301,856,235USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2021-06-309,346,796USD
At 2020-09-309,346,796USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-04-01 to 2021-06-305,984,406USD91
2020-10-01 to 2021-06-3018,328,651USD273
2020-04-01 to 2020-06-304,688,891USD91
2019-10-01 to 2020-06-3013,569,911USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-04-01 to 2021-06-302,203,748USD91
2020-10-01 to 2021-06-309,946,268USD273
2020-04-01 to 2020-06-302,644,244USD91
2019-10-01 to 2020-06-307,324,730USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-06-30145,979,429shares
At 2020-09-3055,576,996shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-06-30227,622,330USD
At 2020-09-30104,208,958USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2021-06-30137,281,953USD
At 2021-03-31125,762,166USD
At 2020-12-3125,800,841USD
At 2020-09-3033,670,668USD
At 2020-06-3028,742,062USD
At 2020-03-3125,217,907USD
At 2019-12-3123,150,992USD
At 2019-09-3027,152,872USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-06-30864,865USD
At 2020-09-30986,204USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2021-06-30897,325USD
At 2020-09-301,014,470USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2021-06-30366,736USD
At 2020-09-30164,040USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2021-06-304,985,800USD
At 2020-09-304,985,800USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2021-04-01 to 2021-06-30-5,824,008USD91
2021-01-01 to 2021-03-31-4,122,432USD90
2020-10-01 to 2020-12-31-8,146,909USD92
2020-04-01 to 2020-06-30-4,680,118USD91
2020-01-01 to 2020-03-31-4,424,969USD91
2019-10-01 to 2019-12-31-4,322,370USD92

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2021-04-01 to 2021-06-30-7,274,884USD91
2020-10-01 to 2021-06-30-19,544,225USD273
2020-04-01 to 2020-06-30-4,680,118USD91
2019-10-01 to 2020-06-30-13,427,457USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-04-01 to 2021-06-303,407,088USD91
2020-10-01 to 2021-06-307,389,269USD273
2020-04-01 to 2020-06-301,869,636USD91
2019-10-01 to 2020-06-305,690,953USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-10-01 to 2021-06-30761USD273
2019-10-01 to 2020-06-30632USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2021-04-01 to 2021-06-30160,398USD91
2020-10-01 to 2021-06-30235,302USD273
2020-04-01 to 2020-06-308,773USD91
2019-10-01 to 2020-06-30142,454USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2020-10-01 to 2021-06-3082,634USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-10-01 to 2021-06-30-501,571USD273
2019-10-01 to 2020-06-30-901,918USD274

Inspect the source

Entity
Citius Pharmaceuticals, Inc. / CIK 0001506251
Captured
SEC response SHA-256
dab437b1abcb106ce657672edecf4aab637b5713b2c1870820e246433043b176

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001506251.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))